Aug 11: J&Js Janssen got the FDAs greenlight for its PARP inhibitor Akeega (niraparib and abiraterone acetate), which is now authorized to treat BRCA-mutated metastatic castration-resistant prostate cancer
By improving glucose removal in white adipose tissue, tirzepatide restored insulin sensitivity even when there was no GLP- 1 receptor -induced weight loss
Multiple Phase 3 clinical trials in human subjects show sustained weight loss averaging 15-22% of body weight at higher doses, along with major HbA1c reductions, improved glycemic control, visceral fat reduction, and better lipid profiles
High-quality, third-party tested supplements
& Jensen, J
Mass Spectrometry ensures that the delicate, complex amino acid sequence of the peptide is perfectly intact, rather than broken or degraded